Humana

Current directors and officers who also hold a role at another S&P 500 company.

• Frank A. DamelioHPE · DirectorVTRS · DirectorZTS · Director
• Wayne A.I FrederickPODD · DirectorWDAY · Director
• David T. FeinbergEW · Director
• Gordon SmithCMCSA · Director
• Jorge S. MesquitaMDLZ · Director
• Marcy S. KlevornNTRS · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Jul 29, 2026

   (d) On July 28, 2026, the Board of Directors (the “Board”) of Humana Inc. (the “Company”) expanded its number of authorized directors from eleven to thirteen and elected Frederick J. Crawford and Paul J. Smith as directors of the Company, in each case effective on July 28, 2026. The Board of Directors has determined that Messrs. Crawford and Smith qualify as independent directors under the New York Stock Exchange’s director independence standards. Messrs. Crawford and Smith will each be compensated in accordance with the Company’s director compensation program, the components of which were disclosed in the Company’s proxy statement relating to 2026 Annual Meeting of Stockholders filed with the U.S. Securities and Exchange Commission on March 6, 2026. In accordance with this program, Messrs.

   Read the 8-K filing
2. Apr 10, 2026

   (d) On April 10, 2026, the Board of Directors (the “Board”) of Humana Inc. (the “Company”) expanded its number of authorized directors from ten to eleven and elected Robert S. Field as a director of the Company, in each case effective immediately following the adjournment of the Humana Inc. 2026 Annual Meeting of Stockholders on April 16, 2026. The Board of Directors has determined Mr. Field qualifies as an independent director under the New York Stock Exchange’s director independence standards. Mr. Field will be compensated in accordance with the Company’s director compensation program, the components of which are disclosed in the Company’s proxy statement relating to 2026 Annual Meeting of Stockholders filed with the U.S. Securities and Exchange Commission on March 6, 2026. In accordance with this program, Mr.

   Read the 8-K filing
3. Dec 16, 2025

   (b) and (e) On December 16, 2025, Humana Inc. (the “Company”) announced that after a successful 29-year career at the Company, George Renaudin, Insurance Segment President and member of the Company’s Enterprise Leadership Team, will retire by the third quarter of 2026 (the “Transition Date”). Mr. Renaudin has agreed to serve in an advisory capacity to the Company after his transition date. In connection with his advisory service, Mr. Renaudin entered into an agreement with the Company (the “Agreement”), the material terms of which are summarized below. The payments and benefits to which Mr. Renaudin is entitled under the Agreement are generally subject to his compliance with the terms and conditions of the Agreement. Pursuant to the terms of the Agreement, Mr.

   Read the 8-K filing
4. Dec 3, 2024

   (b), (c) and (e) On December 3, 2024, Humana Inc. (the “Company”) announced that in order to pursue personal and professional goals, Susan M. Diamond will be transitioning from her current role as Chief Financial Officer on January 10, 2025 (the “Transition Date”), after which she has agreed to serve in an advisory capacity to the Company through December 31, 2025 (the “Transition Period”). Ms. Diamond’s departure is not related to any disagreement with the Company, including with respect to the Company’s operations, policies or practices. In connection with the transition, Ms. Diamond entered into an agreement with the Company (the “Agreement”), the material terms of which are summarized below. The payments and benefits to which Ms. Diamond is entitled under the Agreement are generally subject to Ms. Diamond’s compliance with the terms and conditions of the Agreement.

   Read the 8-K filing
5. Oct 23, 2024

   (d) Effective October 23, 2024, the Board of Directors (the “Board”) of Humana Inc. (the “Company”) expanded its number of authorized directors from eleven to twelve and elected Gordon Smith as a director of the Company. The Board of Directors has determined that (i) Mr. Smith is independent within the meaning of the New York Stock Exchange’s director independence standards; and (ii) there are no material transactions involving Mr. Smith and the Company. Mr. Smith will be compensated in accordance with the Company’s standard compensation policies and practices for the Board, the components of which were disclosed by the Company in its current report on Form 8-K filed with the U.S. Securities and Exchange Commission on August 21, 2023. In connection with his election to the Board, Mr.

   Read the 8-K filing
6. May 13, 2024

   (a), (b), (c), (d) and (e) On October 11, 2023, Humana Inc. (the “Company”) announced that Bruce D. Broussard, Chief Executive Officer, would be stepping down from that role in the latter half of 2024 and that James A. Rechtin would become President and Chief Executive Officer at that time. The Company is now announcing that the date of that transition is expected to be July 1, 2024 (the “Transition Date”). In connection with the transition, Mr. Broussard entered into an agreement with the Company, dated as of May 13, 2024 (the “Agreement”), the material terms of which are summarized below. The payments and benefits to which Mr. Broussard is entitled under the Agreement are generally subject to Mr. Broussard’s compliance with the terms and conditions of the Agreement. Pursuant to the terms of the Agreement, Mr.

   Read the 8-K filing
7. Oct 11, 2023

   (b) and (c) On October 11, 2023, Humana Inc. (the “Company”) announced the election of James A. Rechtin (“Mr. Rechtin”), age 52, to serve as the Company’s President and Chief Operating Officer, effective as of the later of (x) January 8, 2024, or (y) commencement of his employment with the Company. Bruce D. Broussard, who is currently President and Chief Executive Officer of the Company, will continue to serve as Chief Executive Officer of the Company upon the commencement of Mr. Rechtin’s employment. As part of a multi-year succession plan, the Company expects that Mr. Broussard will step down as Chief Executive Officer in the latter half of 2024 and that Mr. Rechtin would become President and Chief Executive Officer at that time. See the attached Press Release for additional biographical information concerning Mr. Rechtin. There are no arrangements or understandings between Mr.

   Read the 8-K filing
8. Aug 21, 2023

   (e) On August 17, 2023, the Board of Directors (the “Board”) of Humana Inc. (the “Company”), upon the recommendation of the Organization & Compensation Committee (the “Committee”) of the Board as advised by the Committee’s independent compensation consultant, approved the following revised schedule for non-employee director compensation, effective as of January 1, 2024: Non-Employee Director Annual Retainer $125,000 (1) Non-Employee Chairman of the Board Additional Annual Retainer $240,000 Committee Chairman fee per year: 1. Audit Committee Chair $25,000 2. Organization & Compensation Committee Chair $20,000 3. Nominating, Governance & Sustainability Committee Chair $20,000 (2) 4.

   Read the 8-K filing
9. Sep 15, 2022

   (d) Effective September 15, 2022, the Board of Directors (the “Board”) of Humana Inc. (the “Company”) expanded its number of authorized directors from thirteen to fourteen and elected Brad D. Smith as a director of the Company. The Board of Directors has determined that (i) Mr. Smith is independent within the meaning of the New York Stock Exchange’s director independence standards; and (ii) there are no material transactions involving Mr. Smith and the Company. Under the agreement dated as of February 21, 2022 (the “Agreement”), between the Company and Starboard Value LP and certain of its affiliated entities and natural persons as set forth in the

   Read the 8-K filing
10. Jul 27, 2022

    (b) and (e) On July 27, 2022, Humana Inc. (the “Company”) announced that Timothy Alan Wheatley, Segment President, Retail, will be transitioning from his current role as of December 31, 2022, after which he has agreed to serve in an advisory capacity to the Company through March 1, 2024 (the “Transition Period”) to ensure a smooth transition of the Company’s Retail Segment operations. In connection with the transition, Mr. Wheatley entered into an agreement with the Company, dated as of July 25, 2022 (the “Transition Agreement”), which provides that during the Transition Period he will provide advisory services with respect to the Company’s Retail Segment operations. Until December 31, 2023, Mr.

    Read the 8-K filing
11. Jun 21, 2022

    (b) Humana Inc. (“Humana” or the “Company”) is today announcing that Michael A. Koeberlein will retire from the Company as Senior Vice President, Chief Accounting Officer and Controller, effective August 1, 2022, for personal health reasons. (c) On June 16, 2022, the Board of Directors of the Company elected John-Paul W. Felter to serve as Senior Vice President, Chief Accounting Officer and Controller, effective as of August 1, 2022. As Chief Accounting Officer, Mr. Felter will act as the Company’s principal accounting officer having responsibility for all accounting functions, the establishment and maintenance of internal accounting controls and enterprise-wide financial reporting to both the U.S. Securities and Exchange Commission and state Departments of Insurance. Mr. Felter, age 39, joins the Company from OneAmerica Financial Partners, Inc.

    Read the 8-K filing
12. Mar 1, 2022

    (b) Humana Inc. (“Humana” or the “Company”) is today announcing that, after a twenty-four-year career, Cynthia H. Zipperle will retire from the Company. Ms. Zipperle will continue in her current role as the Company’s Senior Vice President, Chief Accounting Officer and Controller until March 31, 2022, and has agreed to continue to serve as an advisor to the Company through December 31, 2022 to assist with the planned transition. (c) On February 28, 2022, the Board of Directors of the Company elected Michael A. Koeberlein, Ms. Zipperle’s long-planned successor, to serve as Senior Vice President, Chief Accounting Officer and Controller, effective as of March 31, 2022. As Chief Accounting Officer, Mr.

    Read the 8-K filing
13. Mar 1, 2022

    (d) Effective March 1, 2022, the Board of Directors (the “Board”) of Humana Inc. (the “Company”) expanded its number of authorized directors from thirteen to fourteen and elected David T. Feinberg, M.D. as a director of the Company. The Board of Directors has determined that (i) Dr. Feinberg is independent within the meaning of the New York Stock Exchange’s director independence standards; and (ii) there are no material transactions involving Dr. Feinberg and the Company. Under the agreement dated as of February 21, 2022 (the “Agreement”), between the Company and Starboard Value LP and certain of its affiliated entities and natural persons as set forth in the

    Read the 8-K filing
14. Aug 20, 2021

    (e) On August 19, 2021, the Board of Directors (the “Board”) of Humana Inc. (the “Company”), upon the recommendation of the Organization & Compensation Committee of the Board as advised by the Committee’s independent compensation consultant, approved the following revised schedule for director compensation, effective as of January 1, 2022: Non-Employee Director Annual Retainer $120,000 (1) Non-Employee Chairman of the Board Additional Annual Retainer $240,000 (2) Committee Chairman fee per year: 1. Audit Committee Chair $25,000 2. Organization & Compensation Committee Chair $20,000 3.

    Read the 8-K filing
15. Jun 28, 2021

    (c) On June 28, 2021, Humana Inc. (the “Company”) announced that, effective immediately, Susan M. Diamond has been elected by the Company’s Board of Directors as Chief Financial Officer. Ms. Diamond, age 48, has served as Segment President, Home Business and Interim Chief Financial Officer, since her election to that role on June 1, 2021, having previously served as Segment President, Home Business since her election in July 2019. Ms. Diamond joined the Company in June 2004 and has spent the majority of her Humana career in various leadership roles in the Medicare business, with a particular passion and emphasis on growth and consumer segmentation strategies for the Company’s individual Medicare Advantage and Stand Alone Part D offerings. Ms.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.